Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1997 1
2001 1
2003 2
2005 1
2006 1
2007 1
2008 2
2009 4
2010 3
2011 6
2012 7
2013 12
2014 10
2015 7
2016 7
2017 13
2018 14
2019 14
2020 18
2021 35
2022 22
2023 29
2024 29
2025 37
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Simman, 5BAuthor
Page 1
Semaglutide for adults living with obesity.
Bracchiglione J, Meza N, Franco JV, Escobar Liquitay CM, Novik A V, Ocara Vargas M, Lazcano G, Poloni D, Rinaldi Langlotz F, Roqué-Figuls M, Munoz SR, Madrid E. Bracchiglione J, et al. Cochrane Database Syst Rev. 2025 Oct 30;10(10):CD015092. doi: 10.1002/14651858.CD015092.pub2. Cochrane Database Syst Rev. 2025. PMID: 41161683
Semaglutide may increase non-serious adverse events (RR 1.11, 95% CI 1.01 to 1.22; 13 studies, 8443 participants; low-certainty evidence), likely results in little to no absolute difference in adverse events leading to withdrawal (RR 1.84, 95% CI 1.53 to 2.21; 15 studies, …
Semaglutide may increase non-serious adverse events (RR 1.11, 95% CI 1.01 to 1.22; 13 studies, 8443 participants; low-certainty evide …
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Free article. Clinical Trial.
Assessments based on prior exposure to biologics included Hidradenitis Suppurativa Clinical Response (HiSCR), abscess and inflammatory nodule (AN) count, flare rates, HS-related pain [numerical rating scale 30 (NRS30)], 55% reduction in the International Hidradenitis Suppurativa …
Assessments based on prior exposure to biologics included Hidradenitis Suppurativa Clinical Response (HiSCR), abscess and inflammatory nodul …
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.
Strand V, Kalunian KC, Lee KW, Seo C, Abreu G, Tummala R, Al-Mossawi H, Duncan EA, Lindholm C. Strand V, et al. Lancet Rheumatol. 2025 Jul;7(7):e485-e494. doi: 10.1016/S2665-9913(25)00022-0. Epub 2025 May 2. Lancet Rheumatol. 2025. PMID: 40324450 Clinical Trial.
Exploratory endpoints were changes from baseline in patient-reported outcomes (Short Form-36 version 2 acute recall [SF-36v2 (acute)], Patient Global Assessment of disease activity, EuroQoL 5 Dimensions-5 Levels [EQ-5D-5L], and Work Productivity and Activity Impairment-Lup …
Exploratory endpoints were changes from baseline in patient-reported outcomes (Short Form-36 version 2 acute recall [SF-36v2 (acute)], Patie …
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM. Wortelboer N, et al. Eur J Cancer. 2025 Dec 9;231:116051. doi: 10.1016/j.ejca.2025.116051. Epub 2025 Oct 25. Eur J Cancer. 2025. PMID: 41207182 Free article. Clinical Trial.
Quality-adjusted life-years (QALYs) were estimated using EQ-5D-5L questionnaires. Hospital resource use was collected while on SONIA treatment and cancer medications until the end of follow-up. ...Healthcare costs were higher among patients receiving CDK4/6i in first- vers …
Quality-adjusted life-years (QALYs) were estimated using EQ-5D-5L questionnaires. Hospital resource use was collected while on SONIA …
Biomimetic fractal topography enhances podocyte maturation in vitro.
Liu C, Aggarwal P, Wagner KT, Landau S, Cui T, Song X, Shamaei L, Rafatian N, Zhao Y, Rodriguez-Ramirez S, Morton K, Virlee E, Li CY, Bannerman D, Pascual-Gil S, Okhovatian S, Radisic A, Clotet-Freixas S, Veres T, Sadrzadeh M, Filleter T, Broeckel U, Konvalinka A, Radisic M. Liu C, et al. Nat Commun. 2025 Dec 15;16(1):11116. doi: 10.1038/s41467-025-66037-8. Nat Commun. 2025. PMID: 41398144 Free PMC article.
Mitochondrial Dysfunction Contributes to Sustained Muscle Loss After Cardiac Surgery: A Prospective Observational Study.
Thomas AN, Kalakoutas A, Yates M, Yap J, Sanders J, Kemp P, Griffiths MJD. Thomas AN, et al. J Cachexia Sarcopenia Muscle. 2025 Aug;16(4):e70051. doi: 10.1002/jcsm.70051. J Cachexia Sarcopenia Muscle. 2025. PMID: 40842041 Free PMC article.
Proportionate mean loss of RFcsa between pre-op and Day 7 values was 6.44% [95% CI 4.21 to 8.68, n = 31]; between pre-op and follow-up 9.69% [95% CI 4.92 to 14.96, n = 22]; and between Day 7 and follow-up 3.60% [95% CI -1.30 to 8.48, n = 22]. By contrast to measures …
Proportionate mean loss of RFcsa between pre-op and Day 7 values was 6.44% [95% CI 4.21 to 8.68, n = 31]; between pre-op and follow-up 9.69% …
Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.
Bradley CP, McKinley G, Orchard V, Tiller C, Stanley B, Ang D, Morrow AJ, Sykes R, Gildea P, Petty M, Brogan R, Carrick D, Collison D, Eteiba H, Ghattas A, Good R, Joshi F, Lindsay M, McCartney P, McGowan J, McGeoch R, Robertson K, Rocchiccioli P, Shaukat A, Watkins S, Kellman P, McConnachie A, Berry C. Bradley CP, et al. Nat Med. 2026 Jan;32(1):332-341. doi: 10.1038/s41591-025-04044-4. Epub 2025 Nov 10. Nat Med. 2026. PMID: 41214345 Free PMC article. Clinical Trial.
SAQ summary scores at 12 months in the intervention and control groups were 70.9 23.6 (21.7 22.6 change from baseline) and 52.1 24.1 (-0.8 20.4 change from baseline) (adjusted mean difference: 20.9 (95% confidence interval: 15.8-26.0)), respectively, indicating tha …
SAQ summary scores at 12 months in the intervention and control groups were 70.9 23.6 (21.7 22.6 change from baseline) and 52.1 …
Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study.
Cardona-Roca L, Seguí-Solanes C, Cano-Alonso M, Sosa-Pons A, Almendros-Abad N, Sola NR. Cardona-Roca L, et al. BMC Neurol. 2025 Oct 14;25(1):418. doi: 10.1186/s12883-025-04384-1. BMC Neurol. 2025. PMID: 41087959 Free PMC article.

Treatment satisfaction was correlated with a reduction in HIT-6 score (r = 0.372, p < 0.001). At 1 year, significant improvements were observed in the EQ-5D-5L index score and visual analog scale. ...Fifty-three patients (66%) achieved a 6-point reduction on th

…

Treatment satisfaction was correlated with a reduction in HIT-6 score (r = 0.372, p < 0.001). At 1 year, significant improvements

…
264 results